We included both patients with astrocytomas grade 3 and 4 because the primary endpoint of this study was safety and tolerability; however, this certainly complicates interpretation of efficacy as IDH-mutant and/or MGMT promoter methylated gliomas may well respond to TMZ alone. This evidence concerns the gene MGMT and astrocytoma (excluding glioblastoma).